Genotox Laboratories is a leading diagnostics provider in the field of pain management, addiction, psychiatry, and primary care. Our company vision is to deliver the industry standard for disease identification markers powered by unique, genetically guided signals. The development of our patented technology complimented by high resolution mass spectrometry and genetic sequencing capabilities position Genotox as a leading partner in preventative medicine initiatives. As the model of healthcare shifts from reactionary to preventative, the specialty diagnostics industry will continue to be a high value partner to all industry stakeholders, including patients, clinicians, healthcare systems, and healthcare insurance companies. According to the National Institutes of Health, “the most effective way to help someone with a substance use problem who may be at risk for developing a substance use disorder is to intervene early, before the condition can progress.” Identifying a signal of disease progression as early as possible is a best practice. In the process of treating and managing the presence of the disease, it is vital to identify underlying and potentially hidden disease signals. Studies on over 400,000 patients show that Genotox will identify between 2-7% more cases of possible disease versus alternative diagnostic testing options. Our primary value proposition is in early intervention and treatment. Genotox’ suite of proprietary diagnostics play a key role in the pursuit of reducing overdose mortality rates and costly emergency room visits as well as improving recovery treatment outcomes and population health overall.
